Efficacy and safety of 1.5% and 1% pilocarpine eyedrop combined with 0.1% brimonidine compared to 1.25% pilocarpine eyedrop in presbyopia treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220930004

Enrollment

Registered

2022-09-30

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy and safety of 1.5% and 1% pilocarpine eyedrop combined with 0.1% brimonidine compared to 1.25% pilocarpine eyedrop in presbyopia treatment Pilocarpine, Brimonidine, presbyopia treatment

Interventions

1) Age 40-60 years with VA least 6/6 in both eyes 2) Measured by autorefractor +/- 0.5 D and astigmatism does not exceed 0.5 D 3) Presbyopia Diagnosed by reading Rosenbaum Near VA at 14 inches, not J1

Treatment

Presbyopia

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Age 40-60 years with VA least 6/6 in both eyes 2) Measured by autorefractor +/- 0.5 D and astigmatism does not exceed 0.5 D 3) Presbyopia Diagnosed by reading Rosenbaum Near VA at 14 inches, not J1+

Exclusion criteria

Exclusion criteria: 1) Astigmatism more than 0.5 D 2) History of glaucoma, cataract, retinal detachment or other eye diseases obscuring vision 3) Taking medications such as psychiatric drugs, anticholinergic drugs or other drugs

Design outcomes

Primary

Measure	Time frame
Uncorrected distance visual acuity (UDVA) at visit 1,2,3,4,5,6 ETDRS chart at 4 m.	—

Secondary

Measure	Time frame
Uncorrected near visual acuity (UNVA) at visit 1,2,3,4,5,6 Rosenbaum Near chart at 14 inch	—

Countries

Thailand

Contacts

Public ContactAssoc.Prof.Thammanoon Surachatkumtonekul

Faculty of Medicine Siriraj Hospital, Mahidol University

si95thim@gmail.com024198037

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026